The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Current standard treatment options for pStage III gastric or G/GEJ cancer
Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, Nagaizumi, Japan, discusses the current standard treatment options for postoperative adjuvant therapy in pathologic stage III gastric or gastroesophageal junction (G/GEJ) cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
